NASDAQ:TELO Telomir Pharmaceuticals Q3 2026 Earnings Results & Report $0.57 -0.12 (-16.81%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Telomir Pharmaceuticals beat analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$0.01 versus the -$0.03 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeAfter Market Closes Telomir Pharmaceuticals EPS ResultsActual EPS-$0.01Consensus EPS -$0.03Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersTelomir Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$500 thousandBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTelomir Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Telomir Pharmaceuticals Q3 2026 Earnings FAQ Did Telomir Pharmaceuticals beat earnings estimates for Q3 2026? Telomir Pharmaceuticals (NASDAQ:TELO) reported earnings of -$0.01 per share for Q3 2026, beating the consensus estimate of -$0.03. The report was announced on Friday, November 6, 2026. When is Telomir Pharmaceuticals' next earnings date? Telomir Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Telomir Pharmaceuticals on the company's earnings history page. Telomir Pharmaceuticals Earnings HeadlinesTelomir Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 7 at 9:34 AM | marketscreener.comMTelomir Pharmaceuticals, Inc. announced that it has received $5.618228 million in fundingOctober 6, 2026 | marketscreener.comMMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.November 10 at 1:00 AM | Porter & Company (Ad)Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyOctober 6, 2026 | globenewswire.comResearch shows Telomir-Zn might slow bone cancer in dogsSeptember 24, 2026 | msn.comMaxim Initiates Telomir Pharmaceuticals at Buy With $4 Price TargetSeptember 18, 2026 | marketscreener.comMSee More Telomir Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email. Email Address About Telomir PharmaceuticalsTelomir Pharmaceuticals (NASDAQ:TELO) is a development-stage biotechnology company focused on therapies intended to address age-related diseases and conditions. The company’s research is centered on telomere biology, a field involving the protective DNA sequences at the ends of chromosomes that are associated with cellular aging. Telomir’s lead investigational product is TELOMIR-1, an orally administered small-molecule compound being developed to promote telomere lengthening and support cellular health. The company is evaluating potential applications in human medicine and veterinary medicine, although TELOMIR-1 remains investigational and has not been established as a safe or effective treatment for any disease. Telomir Pharmaceuticals is headquartered in Jacksonville, Florida, and its shares trade on the Nasdaq Capital Market under the symbol TELO. As a biotechnology company in the research and development stage, it does not currently have an approved commercial product.View Telomir Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
